BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season - 2EU waters down plans to end new petrol and diesel car sales by 2035
- 3Prehistoric wolf’s gut frozen in time reveals an ice age giant
- 4What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- 5Vote in favor of the juice that you love for its medical advantages!
- Farmers call for French blockades over cow disease cull
- Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
- 80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- Vote In favor of Your Favored Shades
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- Relentless rise in carbon pollution from fossil fuels slightly dampens climate-fighting hopes
- Weather forecast, Turkana style: A goat's intestines tell it all
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
